Bioactive Materials ( IF 18.9 ) Pub Date : 2021-08-20 , DOI: 10.1016/j.bioactmat.2021.08.005 Tongtong Zhu 1 , Mengyang Jiang 2 , Mingran Zhang 1, 3 , Liguo Cui 3 , Xiaoyu Yang 3 , Xukai Wang 1 , Guangyao Liu 1 , Jianxun Ding 3 , Xuesi Chen 3
Osteonecrosis is a common orthopedic disease in clinic, resulting in joint collapse if no appropriate treatment is performed in time. Core decompression is a general treatment modality for early osteonecrosis. However, effective bone regeneration in the necrotic area is still a significant challenge. This study developed a biofunctionalized composite scaffold (PLGA/nHA30VEGF) for osteonecrosis therapy through potentiation of osteoconduction, angiogenesis, and a favorable metabolic microenvironment. The composite scaffold had a porosity of 87.7% and compressive strength of 8.9 MPa. PLGA/nHA30VEGF had an average pore size of 227.6 μm and a water contact angle of 56.5° with a sustained release profile of vascular endothelial growth factor (VEGF). After the implantation of PLGA/nHA30VEGF, various osteogenic and angiogenic biomarkers were upregulated by 2–9 fold compared with no treatment. Additionally, the metabolomic and lipidomic profiling studies demonstrated that PLGA/nHA30VEGF effectively regulated the multiple metabolites and more than 20 inordinate metabolic pathways in osteonecrosis. The excellent performances reveal that the biofunctionalized composite scaffold provides an advanced adjuvant therapy modality for osteonecrosis.
中文翻译:
生物功能化复合支架可增强骨传导、血管生成和用于骨坏死治疗的有利代谢微环境
骨坏死是临床上常见的骨科疾病,如果不及时进行适当的治疗,会导致关节塌陷。核心减压是早期骨坏死的一般治疗方式。然而,坏死区域的有效骨再生仍然是一个重大挑战。本研究开发了一种生物功能化复合支架 (PLGA/nHA 30 VEGF ),通过增强骨传导、血管生成和有利的代谢微环境来治疗骨坏死。复合支架的孔隙率为 87.7%,抗压强度为 8.9 MPa。PLGA/nHA 30 VEGF平均孔径为 227.6 μm,水接触角为 56.5°,具有血管内皮生长因子 (VEGF) 的缓释曲线。植入 PLGA/nHA 30 VEGF 后,与未治疗相比,各种成骨和血管生成生物标志物上调了 2-9 倍。此外,代谢组学和脂质组学分析表明,PLGA/nHA 30 VEGF 可有效调节骨坏死中的多种代谢物和 20 多种异常代谢途径。优异的性能表明,生物功能化复合支架为骨坏死提供了一种先进的辅助治疗方式。